Mobile

A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and e...

Mise à jour : Il y a 4 ans
Référence : EUCTR2009-014986-22

A randomized double blind, placebo-controlled clinical trial to assess the effects of taspoglutide (RO5073031) on cardiovascular outcomes in subjects with inadequately controlled type 2 diabetes and established cardiovascular disease

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

The primary objective is to determine the effect of taspoglutide in addition to standard of care on cardiovascular outcomes in type 2 diabetic subjects with established cardiovascular disease in order to rule out an unacceptable (80%) increase in cardiovascular events.

Critère d'inclusion

  • Patients with Type 2 diabetes

Liens